However, baricitinib, a JAK inhibitor acting on JAK1/2 identified as a candidate medicine using artificial intelligence (36), is used for the treatment of severe pneumonia in patients with COVID-19, together with remdesivir, an antiviral medicine (13, 37). Here, JAK1 is linked to susceptibility to pneumonia measurement.